Previous 10 | Next 10 |
Novocure (NASDAQ: NVCR) today announced the launch of MyLink, a new tool that allows patients to download their Optune usage data from the comfort of home without the need for an in-person visit by a Novocure Device Support Specialist. Novocure initiated a phased launch with an initial wave o...
COVID-19 Pandemic Sorrento Therapeutics (SRNE), a San Diego-China biotech, reported that its anti-SARS-CoV-2 antibody, STI-1499, completely inhibited SARS-CoV-2 virus infection from interacting with the ACE2 receptor after four days of incubation (see story ). In preclinical studies, the mo...
Optune is the first innovative treatment for glioblastoma approved in China in over 15 years A large, global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding Optune to chemotherapy more than doubled the five-year overall survival rat e 1 Optune is Za...
Investment thesis NovoCure (NVCR) has made impressive progress in developing and commercialising its novel and innovative Tumor Treating Fields therapy technology, which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division, administered via a head-wo...
Image source: The Motley Fool. NovoCure Limited (NASDAQ: NVCR) Q1 2020 Earnings Call May 2, 2020 , 10:00 p.m. ET Operator Continue reading
Axcella Health (NASDAQ: AXLA ) initiated with Buy rating and $10 (115% upside) price target at BTIG Research. More news on: Axcella Health Inc., Viking Therapeutics, Inc., Y-mAbs Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
NovoCure Limited (NVCR) Q1 2020 Earnings Conference Call April 30, 2020 08:00 AM ET Company Participants Ashley Cordova - Senior Vice President of Finance & Investor Relations William Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Wilco Groenhuysen - Chi...
The following slide deck was published by NovoCure Limited in conjunction with their 2020 Q1 earnings Read more ...
NovoCure (NASDAQ: NVCR ): Q1 GAAP EPS of $0.04 beats by $0.02 . More news on: NovoCure Limited, Earnings news and commentary, Healthcare stocks news, Read more ...
Quarterly net revenues of $101.8 million, representing 39 percent growth versus the first quarter 2019 and 3 percent growth versus the fourth quarter 2019 Balance sheet strength allows continued investments in innovation and the advancement of commercial and development priorities ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three...